News from Direct Biologics

Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial

Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial AUSTIN, Texas, April 6, 2022 Direct Biologics, a regenerative biotechnology company with a lifesaving mesenchymal stem cell (MSC) derived extracellular vesicle (EV) platform technology, announces topline results from its first-in-human, multicenter, Phase II double-blind, placebo-controlled, randomized clinical trial, EXIT COVID-19, today which used… Read More »Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial

The post Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial appeared first on Direct Biologics.